Perspective Therapeutics (CATX) Stock Forecast, Price Target & Predictions

CATX Stock Forecast

Perspective Therapeutics stock forecast is as follows: an average price target of $21.75 (represents a 663.16% upside from CATX’s last price of $2.85) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

CATX Price Target

The average price target for Perspective Therapeutics (CATX) is $21.75 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $20.00. This represents a potential 663.16% upside from CATX's last price of $2.85.

CATX Analyst Ratings

Buy

According to 6 Wall Street analysts, Perspective Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CATX stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Perspective Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 24, 2024	David Dai	UBS	$20.00	$11.69	71.09%	601.75%
Oct 14, 2024	Jeff Jones	Oppenheimer	$22.00	$12.66	73.78%	671.93%
Sep 25, 2024	Nicole Germino	Truist Financial	$21.00	$12.28	71.01%	636.84%
Jul 25, 2024	Alec Stranahan	Bank of America Securities	$24.00	$12.82	87.21%	742.11%
Jun 18, 2024	Jeff Jones	Oppenheimer	$19.00	$11.93	59.26%	566.67%
Jun 14, 2024	Gregory Renza	RBC Capital	$3.00	$1.15	161.21%	5.26%
May 15, 2024	Jeff Jones	Oppenheimer	$2.00	$1.57	27.39%	-29.82%

The latest Perspective Therapeutics stock forecast, released on Oct 24, 2024 by David Dai from UBS, set a price target of $20.00, which represents a 71.09% increase from the stock price at the time of the forecast ($11.69), and a 601.75% increase from CATX last price ($2.85).

Perspective Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	3	7
Avg Price Target	-	$21.00	$15.86
Last Closing Price	$2.85	$2.85	$2.85
Upside/Downside	-100.00%	636.84%	456.49%

In the current month, the average price target of Perspective Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Perspective Therapeutics's last price of $2.85. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 24, 2024	UBS		Buy	Initialise
Oct 14, 2024	Oppenheimer	Outperform	Outperform	Hold
Sep 30, 2024	Wedbush		Outperform	Initialise
Jun 18, 2024	Oppenheimer	Outperform	Outperform	Hold
Jun 14, 2024	RBC Capital	Outperform	Outperform	Hold
May 15, 2024	Oppenheimer	Outperform	Outperform	Hold
May 14, 2024	RBC Capital		Outperform	Initialise
May 09, 2024	Cantor Fitzgerald		Overweight	Initialise
Apr 09, 2024	B. Riley	Buy	Buy	Hold
Apr 01, 2024	Oppenheimer	Outperform	Outperform	Hold

Perspective Therapeutics's last stock rating was published by UBS on Oct 24, 2024. The company Initialise its CATX rating from "null" to "Buy".

Perspective Therapeutics Financial Forecast

Perspective Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.50M	$1.83M	$1.83M	$1.72M	$2.50M	$2.91M	$2.82M	$2.56M	$2.71M	$2.60M	$2.36M	$2.38M	$2.28M	$2.88M	$2.21M
Avg Forecast	-	-	-	-	$100.80K	$99.80K	$98.81K	$147.83K	$297.76K	$292.76K	$183.48K	$368.80K	$1.85M	$2.60M	$2.06M	$2.84M	$2.84M	$2.95M	$2.49M	$2.70M	$2.43M	$2.40M	$2.85M	$2.70M	$2.54M	$2.30M	$2.12M	$1.93M	$1.93M
High Forecast	-	-	-	-	$100.80K	$99.80K	$98.81K	$149.58K	$437.88K	$292.76K	$183.72K	$368.90K	$2.23M	$2.60M	$2.06M	$2.84M	$2.98M	$2.95M	$2.49M	$2.70M	$2.43M	$2.40M	$2.85M	$2.70M	$2.54M	$2.30M	$2.12M	$1.93M	$1.97M
Low Forecast	-	-	-	-	$100.80K	$99.80K	$98.81K	$146.08K	$153.26K	$292.76K	$183.24K	$368.70K	$1.47M	$2.60M	$2.06M	$2.84M	$2.71M	$2.95M	$2.49M	$2.70M	$2.43M	$2.40M	$2.85M	$2.70M	$2.54M	$2.30M	$2.12M	$1.93M	$1.89M
# Analysts	-	-	-	-	1	1	1	4	6	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.73%	0.64%	0.65%	0.58%	1.01%	1.08%	1.16%	1.07%	0.95%	0.96%	0.93%	1.04%	1.08%	1.49%	1.14%

Perspective Therapeutics's average Quarter revenue forecast for Sep 23 based on 1 analysts is $2.60M, with a low forecast of $2.60M, and a high forecast of $2.60M. CATX's average Quarter revenue forecast represents a 73.33% increase compared to the company's last Quarter revenue of $1.50M (Jun 23).

Perspective Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
# Analysts	-	-	-	-	1	1	1	4	6	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-11.08M	$-10.65M	$-3.10M	$-4.21M	$-2.11M	$-1.38M	$-1.64M	$-2.21M	$-1.09M	$-762.00K	$-859.00K	$-714.00K	$-1.19M	$-512.00K	$-864.00K
Avg Forecast	-	-	-	-	$-68.23K	$-67.56K	$-66.89K	$-100.07K	$-201.57K	$-198.19K	$-124.21K	$-249.66K	$-1.25M	$-1.76M	$-1.39M	$-1.93M	$-1.93M	$-1.83M	$-1.55M	$-1.68M	$-1.51M	$-1.49M	$-1.77M	$-1.68M	$-1.58M	$-1.43M	$-1.32M	$-1.20M	$-1.20M
High Forecast	-	-	-	-	$-68.23K	$-67.56K	$-66.89K	$-98.89K	$-103.75K	$-198.19K	$-124.04K	$-249.59K	$-992.43K	$-1.76M	$-1.39M	$-1.93M	$-1.83M	$-1.83M	$-1.55M	$-1.68M	$-1.51M	$-1.49M	$-1.77M	$-1.68M	$-1.58M	$-1.43M	$-1.32M	$-1.20M	$-1.18M
Low Forecast	-	-	-	-	$-68.23K	$-67.56K	$-66.89K	$-101.26K	$-296.42K	$-198.19K	$-124.37K	$-249.73K	$-1.51M	$-1.76M	$-1.39M	$-1.93M	$-2.02M	$-1.83M	$-1.55M	$-1.68M	$-1.51M	$-1.49M	$-1.77M	$-1.68M	$-1.58M	$-1.43M	$-1.32M	$-1.20M	$-1.22M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.94%	5.53%	1.61%	2.29%	1.36%	0.82%	1.08%	1.49%	0.62%	0.45%	0.54%	0.50%	0.90%	0.43%	0.72%

undefined analysts predict CATX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Perspective Therapeutics's previous annual EBITDA (undefined) of $NaN.

Perspective Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
# Analysts	-	-	-	-	1	1	1	4	6	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-11.11M	$-371.00K	$-2.20M	$-3.93M	$-2.01M	$-1.21M	$-1.60M	$-2.24M	$-1.06M	$-745.00K	$-868.00K	$-713.00K	$-1.19M	$-545.00K	$-897.00K
Avg Forecast	$-22.60M	$-21.89M	$-21.19M	$-21.19M	$-27.11M	$-25.44M	$-23.65M	$-21.72M	$-18.81M	$-15.07M	$-14.53M	$-19.78M	$-31.78M	$-21.19M	$84.21M	$-7.06M	$-706.29K	$-21.04M	$-28.06M	$-28.06M	$-28.06M	$-28.06M	$-28.06M	$-37.41M	$-37.41M	$-37.41M	$-46.76M	$-56.11M	$-5.61M
High Forecast	$-22.60M	$-21.89M	$-21.19M	$-21.19M	$-27.11M	$-25.44M	$-23.65M	$-17.65M	$-16.64M	$-15.07M	$-14.53M	$-19.78M	$-31.78M	$-21.19M	$84.21M	$-7.06M	$-706.29K	$-21.04M	$-28.06M	$-28.06M	$-28.06M	$-28.06M	$-28.06M	$-37.41M	$-37.41M	$-37.41M	$-46.76M	$-56.11M	$-5.61M
Low Forecast	$-22.60M	$-21.89M	$-21.19M	$-21.19M	$-27.11M	$-25.44M	$-23.65M	$-25.12M	$-20.98M	$-15.07M	$-14.53M	$-19.78M	$-31.78M	$-21.19M	$84.21M	$-7.06M	$-706.29K	$-21.04M	$-28.06M	$-28.06M	$-28.06M	$-28.06M	$-28.06M	$-37.41M	$-37.41M	$-37.41M	$-46.76M	$-56.11M	$-5.61M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.13%	0.05%	3.11%	0.19%	0.07%	0.04%	0.06%	0.08%	0.04%	0.02%	0.02%	0.02%	0.03%	0.01%	0.16%

Perspective Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CATX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Perspective Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
# Analysts	-	-	-	-	1	1	1	4	6	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$5.98M	$7.83M	$2.99M	$3.91M	$2.24M	$2.27M	$2.32M	$2.60M	$1.97M	$1.76M	$1.75M	$1.65M	$1.94M	$1.96M	$1.74M
Avg Forecast	-	-	-	-	$384.07K	$380.26K	$376.50K	$563.29K	$1.13M	$1.12M	$699.13K	$1.41M	$7.05M	$9.91M	$7.85M	$10.84M	$10.84M	$3.13M	$2.63M	$2.86M	$2.57M	$2.54M	$3.02M	$2.86M	$2.69M	$2.44M	$2.24M	$2.05M	$2.05M
High Forecast	-	-	-	-	$384.07K	$380.26K	$376.50K	$569.96K	$1.67M	$1.12M	$700.04K	$1.41M	$8.51M	$9.91M	$7.85M	$10.84M	$11.35M	$3.13M	$2.63M	$2.86M	$2.57M	$2.54M	$3.02M	$2.86M	$2.69M	$2.44M	$2.24M	$2.05M	$2.09M
Low Forecast	-	-	-	-	$384.07K	$380.26K	$376.50K	$556.62K	$583.97K	$1.12M	$698.21K	$1.40M	$5.59M	$9.91M	$7.85M	$10.84M	$10.33M	$3.13M	$2.63M	$2.86M	$2.57M	$2.54M	$3.02M	$2.86M	$2.69M	$2.44M	$2.24M	$2.05M	$2.01M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.76%	0.72%	0.28%	1.25%	0.85%	0.79%	0.90%	1.02%	0.65%	0.62%	0.65%	0.68%	0.86%	0.96%	0.85%

Perspective Therapeutics's average Quarter SG&A projection for Sep 23 is $9.91M, based on 1 Wall Street analysts, with a range of $9.91M to $9.91M. The forecast indicates a 65.56% rise compared to CATX last annual SG&A of $5.98M (Jun 23).

Perspective Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19
# Analysts	-	-	-	-	1	1	1	4	6	3	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.04	$-0.00	$-0.02	$-0.03	$-0.01	$-0.01	$-0.01	$-0.02	$-0.01	$-0.01	$-0.01	$-0.01	$-0.02	$-0.01	$-0.01
Avg Forecast	$-0.32	$-0.31	$-0.30	$-0.30	$-0.38	$-0.36	$-0.33	$-0.31	$-0.27	$-0.21	$-0.21	$-0.28	$-0.45	$-0.30	$1.19	$-0.10	$-0.01	$-0.07	$-0.10	$-0.10	$-0.10	$-0.10	$-0.10	$-0.13	$-0.13	$-0.13	$-0.17	$-0.20	$-0.02
High Forecast	$-0.32	$-0.31	$-0.30	$-0.30	$-0.38	$-0.36	$-0.33	$-0.25	$-0.24	$-0.21	$-0.21	$-0.28	$-0.45	$-0.30	$1.19	$-0.10	$-0.01	$-0.07	$-0.10	$-0.10	$-0.10	$-0.10	$-0.10	$-0.13	$-0.13	$-0.13	$-0.17	$-0.20	$-0.02
Low Forecast	$-0.32	$-0.31	$-0.30	$-0.30	$-0.38	$-0.36	$-0.33	$-0.36	$-0.30	$-0.21	$-0.21	$-0.28	$-0.45	$-0.30	$1.19	$-0.10	$-0.01	$-0.07	$-0.10	$-0.10	$-0.10	$-0.10	$-0.10	$-0.13	$-0.13	$-0.13	$-0.17	$-0.20	$-0.02
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.03%	0.02%	1.55%	0.37%	0.14%	0.09%	0.11%	0.16%	0.07%	0.05%	0.08%	0.08%	0.10%	0.04%	0.66%

According to undefined Wall Street analysts, Perspective Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CATX previous annual EPS of $NaN (undefined).

Perspective Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
CATX	Perspective Therapeutics	$3.07	$21.75	608.47%	Buy
LUNG	Pulmonx	$6.13	$13.00	112.07%	Buy
SGHT	Sight Sciences	$3.62	$7.50	107.18%	Hold
KIDS	OrthoPediatrics	$22.46	$39.50	75.87%	Buy
HYPR	Hyperfine	$0.94	$1.60	70.21%	Buy
LIVN	LivaNova	$49.94	$68.25	36.66%	Buy
OFIX	Orthofix Medical	$17.93	$24.00	33.85%
SIBN	SI-BONE	$13.84	$18.50	33.67%	Buy
NPCE	NeuroPace	$11.52	$15.00	30.21%	Buy
FNA	Paragon 28	$10.36	$11.50	11.00%	Buy
CVRX	CVRx	$13.16	$14.25	8.28%	Buy
SRDX	Surmodics	$39.96	$39.50	-1.15%	Buy

CATX Forecast FAQ

Is Perspective Therapeutics a good buy?

Yes, according to 6 Wall Street analysts, Perspective Therapeutics (CATX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 100.00% of CATX's total ratings.

What is CATX's price target?

Perspective Therapeutics (CATX) average price target is $21.75 with a range of $20 to $24, implying a 663.16% from its last price of $2.85. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Perspective Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CATX stock, the company can go up by 663.16% (from the last price of $2.85 to the average price target of $21.75), up by 742.11% based on the highest stock price target, and up by 601.75% based on the lowest stock price target.

Can Perspective Therapeutics stock reach $4?

CATX's average twelve months analyst stock price target of $21.75 supports the claim that Perspective Therapeutics can reach $4 in the near future.

What are Perspective Therapeutics's analysts' financial forecasts?

Perspective Therapeutics's analysts financial forecasts for the fiscal year (Jun 2025) are as follows: average revenue is $837.16K (high $979.03K, low $690.91K), average EBITDA is $-567K (high $-468K, low $-663K), average net income is $-79.251M (high $-73.007M, low $-84.816M), average SG&A $3.19M (high $3.73M, low $2.63M), and average EPS is $-1.122 (high $-1.034, low $-1.201). CATX's analysts financial forecasts for the fiscal year (Jun 2026) are as follows: average revenue is $200.59K (high $200.59K, low $200.59K), average EBITDA is $-136K (high $-136K, low $-136K), average net income is $-94.922M (high $-94.922M, low $-94.922M), average SG&A $764.33K (high $764.33K, low $764.33K), and average EPS is $-1.344 (high $-1.344, low $-1.344).

Did the CATX's actual financial results beat the analysts' financial forecasts?

Based on Perspective Therapeutics's last annual report (Jun 2022), the company's revenue was $10.8M, beating the average analysts forecast of $10.01M by 7.87%. Apple's EBITDA was $-7.391M, beating the average prediction of $-6.224M by 18.75%. The company's net income was $-7.153M, missing the average estimation of $-112M by -93.63%. Apple's SG&A was $9.42M, missing the average forecast of $10.61M by -11.15%. Lastly, the company's EPS was $-0.0504, missing the average prediction of $-0.4 by -87.40%. In terms of the last quarterly report (Jun 2023), Perspective Therapeutics's revenue was $1.5M, missing the average analysts' forecast of $2.06M by -27.18%. The company's EBITDA was $-11.078M, beating the average prediction of $-1.395M by 694.40%. Perspective Therapeutics's net income was $-11.106M, missing the average estimation of $84.21M by -113.19%. The company's SG&A was $5.98M, missing the average forecast of $7.85M by -23.76%. Lastly, the company's EPS was $-0.0397, missing the average prediction of $1.19 by -103.33%